SCHEMBL3934679

SCHEMBL3934679

CC(C)(O)C#Cc1ccc(NC(=O)COc2ccc(Br)c(Oc3cc(Cl)cc(C#N)c3)c2F)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.39
PDK1 Q15118 1/20 0.38
PDK2 Q15119 1/20 0.38
PDK3 Q15120 1/20 0.38
PDK4 Q16654 1/20 0.38
TRPM4 Q8TD43 1/20 0.36
SLC2A1 P11166 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP3A4 P08684 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
PSMD14 O00487 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4027648 0.87 CYP3A4 (0.38) KCNH2PDK1PDK2PDK3PDK4
SCHEMBL3938422 0.83 CA1 (0.45) KCNH2SLC22A12
SCHEMBL3937009 0.81 SLC22A12 (0.39) KCNH2TRPM4SLC2A1L3MBTL1NPC1
SCHEMBL3942957 0.80 KCNH2 (0.45) KCNH2SLC2A1L3MBTL1SMN1; SMN2CYP3A4
SCHEMBL4140860 0.79 CA1 (0.47)
SCHEMBL3945671 0.79 SLC2A1 (0.42) KCNH2SLC2A1CYP3A4ALDH1A1MAPT
SCHEMBL3944194 0.79 KCNH2 (0.36) KCNH2TRPM4SLC2A1L3MBTL1NPC1
SCHEMBL3940886 0.78 CA1 (0.48)
SCHEMBL3938386 0.77 POLB (0.44) KCNH2TRPM4SLC2A1L3MBTL1NPC1
SCHEMBL3944827 0.77 CA1 (0.46) SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046731-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-04-15 EP claimed
WO-2008009613-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-24 WO claimed
US-20080020981-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-01-24 US claimed
EP-2046731-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-04-15 EP disclosed
WO-2008009613-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-24 WO disclosed
US-20080020981-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080020981-A1 Non-nucleoside reverse transcriptase inhibitors SAMHD1, HPRT1, NQO2 KCNH2 4114/4885PDK1 1083/4885PDK2 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.